Ischemia and reperfusion injury (IRI) is the main etiology of acute renal failure in native and transplanted kidneys. In the transplantation field, immunosuppressive drugs may play an additional role in acute graft dysfunction. Rapamycin may impair renal regeneration post IRI. Heme oxygenase 1 (HO-1) is a protective gene with anti-inflammatory and anti-apoptotic actions. We investigated whether HO-1 played a role in rapamycin-induced renal dysfunction in an established model of IRI. Rapamycin (3 mg/kg) was administered to mice before being subjected to 45 min of ischemia. Animals subjected to IRI presented with impaired renal function that peaked at 24 h (2.0570.23 mg/dl), decreasing thereafter. Treatment with rapamycin caused even more renal dysfunctions (2.3070.33 mg/dl), sustained up to 120 h after reperfusion (1.5470.4 mg/dl), when compared to the control (0.6370.09 mg/dl, Po0.05). Rapamycin delayed tubular regeneration that was normally higher in the control group at day 5 (68.5372.30 vs 43.6373.11%, Po0.05). HO-1 was markedly upregulated after IRI and its expression was even enhanced by rapamycin (1.32-fold). However, prior induction of HO-1 by cobalt protoporphyrin improved the renal dysfunction imposed by rapamycin, mostly at later time points. These results demonstrated that rapamycin used in ischemic-injured organs could also negatively affect post-transplantation recovery. Modulation of HO-1 expression may represent a feasible approach to limit rapamycin acute toxicity.
Ischemia and reperfusion injury (IRI) is the main etiology of acute renal failure in native and transplanted kidneys. In the transplantation field, immunosuppressive drugs may play an additional role in acute graft dysfunction. Rapamycin may impair renal regeneration post IRI. Heme oxygenase 1 (HO-1) is a protective gene with anti-inflammatory and anti-apoptotic actions. We investigated whether HO-1 played a role in rapamycin-induced renal dysfunction in an established model of IRI. Rapamycin (3 mg/kg) was administered to mice before being subjected to 45 min of ischemia. Animals subjected to IRI presented with impaired renal function that peaked at 24 h (2.0570.23 mg/dl), decreasing thereafter. Treatment with rapamycin caused even more renal dysfunctions (2.3070.33 mg/dl), sustained up to 120 h after reperfusion (1.5470.4 mg/dl), when compared to the control (0.6370.09 mg/dl, Po0.05). Rapamycin delayed tubular regeneration that was normally higher in the control group at day 5 (68.5372.30 vs 43.6373.11%, Po0.05). HO-1 was markedly upregulated after IRI and its expression was even enhanced by rapamycin (1.32-fold). However, prior induction of HO-1 by cobalt protoporphyrin improved the renal dysfunction imposed by rapamycin, mostly at later time points. These results demonstrated that rapamycin used in ischemic-injured organs could also negatively affect post-transplantation recovery. Modulation of HO-1 expression may represent a feasible approach to limit rapamycin acute toxicity. The role of heme oxygenase 1 (HO-1) in rapamycin-induced renal dysfunction after ischemia and reperfusion injury (IRI) was studied. Long-term graft survival is mainly limited by chronic allograft nephropathy. 1 Its natural history tells us that the acute injury is a factor in the early fibrotic damage that ultimately leads to graft loss. 2 IRI is an inflammatory event that causes distinct degrees of cell dysfunction and death, being the most important antigen-independent negative factor associated with chronic allograft nephropathy. [3] [4] [5] [6] [7] [8] New data support the concept that innate and adaptive arms of the immune response participate in different extensions in the pathogenesis of IRI. [9] [10] [11] [12] However, it is worthy to emphasize that renal transplantation recipients are exposed to additional detrimental factors besides interruption of blood flow. Donor antigen recognition and side effects of immunosuppressive drugs might elicit additional insults to a graft already dysfunctional.
Rapamycin is a macrocyclic lactone antibiotic with immunosuppressive properties able to suppress IL-2 receptor signaling via the mammalian target of rapamycins pathway. 13 Clinical data have demonstrated its role in preventing acute renal rejection, preservation of renal function in cyclosporine-induced chronic nephrotoxicity patients, and in reducing tumoral growth. However, some authors have reported side effects with its use such as proteinuria and renal function impairment, even in the native kidney. [14] [15] [16] [17] [18] [19] Lieberthal et al. 19 have just demonstrated that rapamycin could be related to renal tubular regeneration impairment after acute injury through its ability to inhibit cell cycle and to induce apoptosis. It is well documented that the functional and histological organ outcomes depend not only on the nature and intensity of the aggressor, but also on the ability of the tissue to respond in a protective way. Many molecules have intrinsic cytoprotective properties that include anti-apoptotic, antiinflammatory, and anti-oxidant actions. HO-1 (EC 1.14.99.3) comprises three distinct genes, that is, HO-1 (hmox1, P09601), HO-2 (hmox2, P30519) (reviewed in Camara and Soares 20 ), and HO-3 (hmox3, rat; O70453) that probably does not encode a protein. HO-1 and HO-2 are the rate-limiting enzymes in the catabolism of heme, a reaction that yields equimolar amounts of biliverdin, Fe 2 þ , and carbon monoxide (CO). HO-2 is expressed in most cell types whereas HO-1 is not. However, expression of HO-1 is readily increased upon organ IRI becoming the ratelimiting factor in the generation of biliverdin, Fe 2 þ and CO. [21] [22] [23] In this sense, HO-1 acts as a protective protein expressed by endothelial cells that promote better graft viability.
In this study, we investigated whether HO-1 may also play a role in the additional renal function impairment imposed by the immunosuppressive drugs, especially rapamycin. In an established mouse model of acute renal failure, through vessel pedicle occlusion, we observed that rapamycin worsened the renal function and histology. However, upregulation of HO-1 was associated with the improvement of this dysfunction and normalization of tissue morphology.
RESULTS

Rapamycin worsens acute renal function
IRI is a relevant negative factor in early and late renal graft outcomes. Immunosuppressive drugs can also be a negative factor by retarding graft recovery and sustaining the extension phase of acute renal failure. We initially investigated the impact of rapamycin treatment in a renal IRI mouse model. The drug was administered 1 day before and immediately before the surgery. IRI induced a severe renal dysfunction assessed by serum creatinine levels that peaked at 24 h (2.0570.23 mg/dl), decreasing thereafter (48 h: 1.0570.09 mg/dl; 120 h: 0.6370.09 mg/dl) ( Figure 1 ). Interestingly, rapamycin administration was associated with more accentuated impairment in renal function that was significantly higher at 48 (2.1770.6 mg/dl vs ischemic injured only animals Po0.05) and 120 h (1.5470.4 mg/dl Po0.05) than those observed in animals subjected only to IRI. Although, we observed that 24 h after reperfusion, serum creatinine was slightly higher (2.3070.33 mg/dl) than those observed in animals subjected only to IRI, the difference did not reach a statistical significance. It is noteworthy to say that the sham and animals treated only with the drug had similar serum creatinine levels compared with the normal animals (0.5070.08 mg/dl) ( Figure 1a) .
However, in clinical setting organ transplant recipients are under continuous use of immunosuppressive drugs. Then, we questioned whether a daily treatment of rapamycin could impair renal function else well. As seen in Figure 1b , the exposure of rapamycin daily was associated with worse renal function, compared to controls animals. Although the levels were not statistically different from those seen in animals just pre-treated with rapamycin (days À1 and 0), they were considerably higher than controls (24 Morphometric analyses confirmed the functional data described above. Indeed, the pretreatment with rapamycin (days À1 and 0) was associated with higher levels of acute tubular necrosis (ATN) in those animals subjected to IRI, more important at day 1 after reperfusion (54.0772.56 vs 23.6871.95, respectively, Po0.05). The regeneration percentages observed in renal tubules were prominent in IRI animals at 120 h after reperfusion, but severely decreased in those animals treated with rapamycin (68.5372.30 vs 43.6373.11, respectively, Po0.05) (Figure 2 ).
Rapamycin induces early expression of HO-1 expression
HO-1 is a stress-induced enzyme related to cytoprotection through heme degradation end-products. We were interested in evaluating the expression of HO-1 after IRI by quantitative real-time polymerase chain reaction, and more importantly, in those animals pre-treated with the immunosuppressive drug. As previously demonstrated, HO-1 was markedly upregulated after IRI, mainly 24 h (7.0870.58; 48 h, 3.3370.31) after reperfusion, decreasing at 120 h after surgery (1.6870.29). This expression was significantly higher than that observed in sham and normal animals (1.070.05). The prior treatment with rapamycin resulted in 1.32-fold increase in HO-1 mRNA expression at 24 h after reperfusion (9.4071.83), and increased even higher 48 h later (5.4870.28), although we observed only a statistical significance in the later time point when compared to IRI animals (P ¼ 0.690 and P ¼ 0.04, respectively). Conversely, Cobalt protoporphyrin ameliorates rapamycin-induced impairment in renal function after IRI Upregulation of HO-1, before an insult, has been reported to offer tissue protection in different animal injury models. We addressed the question of how the induced expression of HO-1 would be associated with amelioration of renal function and tissue architecture in animals subjected to IRI, but pre-treated with rapamycin. First, we observed that the administration of cobalt protoporphyrin (COPPIX) resulted in better renal function in those animals subjected to IRI, as demonstrated by a significant decrease in serum creatinine levels at early and regeneration time points. Indeed, at 24 and 120 h after reperfusion, serum creatinine had decreased to 0.7570.1 and 0.5670.06 mg/dl, respectively ( Figure 4a ). When compared to animals just subjected to IRI, we observed a significant difference only 24 h after reperfusion (P ¼ 0.011). The data obtained with sham and sham-treated animals did not differ (Figure 4a ).
Interestingly, COPPIX administration in animals subjected to IRI and pre-treated with rapamycin was followed by a noticeable improvement in renal function. Twentyfour hours after reperfusion, serum creatinine levels reached 1.0370.3 mg/dl, significantly lower than those seen in rapamycin-treated animals (Po0.01). Surprisingly, at later time points where we had previously observed a . Morphometric analyses were performed in 25 random fields in the outer medulla and compared at two time points after reperfusion. Animals subjected to IRI and pre-treated with rapamycin presented higher levels of ATN at 24 and 120 h (*Po0.05) and impaired regeneration at 120 h (*Po0.05), compared to IRI animals. . HO-1 mRNA was markedly upregulated after IRI; however, rapamycin pre-treatment induced an even higher expression, significantly at 48 h after reperfusion (*Po0.05).
negative impact of rapamycin therapy on renal function, the induction of HO-1 was associated with normalization of renal function (0.7070.15 mg/dl, P ¼ 0.004) (Figure 4a ). HO-1 mRNA was markedly upregulated after COPPIX, mainly at the later time points (24 h: 10.272.9; 120 h: 2.2470.7) (Figure 4b ). More strikingly, COPPIX was able to enhance HO-1, even when rapamycin was administered, 24 (4578.2) and 120 h (7.4373.2) after reperfusion, coinciding with the observed improvement in renal function. Additionally, we questioned whether the time of administration of COPPIX, and consequently the chemical induction of HO-1, would make the same benefit on renal function in animals pre-treated or not with rapamycin. For that purpose, animals were treated with COPPIX at the same time of surgery (day 0) or 24 h after surgery (day þ 1), being pretreated or not with rapamycin (days À1 and 0). All animals in these groups were killed 24 h after COPPIX administration. As seen in Figure 5a , late administration of COPPIX did not restore renal function in animals subjected to IRI, pretreated or not with rapamycin. Interestingly, the late administration of COPPIX could nevertheless increase HO-1 mRNA expression (Figure 5b ).
On the other hand, we tested whether the blockade of HO-1 expression by tin protoporphyrin (SnPPIX) would interfere with rapamycin-induced renal dysfunction in those animals subjected to IRI. As a matter of fact, SnPPIX treatment exacerbated renal dysfunction in animals subjected to IRI and in those that were pre-treated with rapamycin. Specifically, SnPPIX administration blocked HO-1 upregulation at 24 h (2.3870.56) after ischemia, even in those animals pre-treated with rapamycin (3.0370.98). These actions reflected in renal function, where we observed . COPPIX significantly decreased renal dysfunction in animals just subjected to IRI (*vs IRI, P ¼ 0.011), and more strikingly, in those pre-treated with rapamycin (**vs rapamycin-treated animals subjected to IRI, Po0.01). Interestingly, at 120 h after reperfusion, COPPIX normalized renal function in animals pre-treated with rapamycin and subjected to IRI (***vs rapamycin-treated animals subjected to IRI, P ¼ 0.004). (b) HO-1 mRNA expression after IRI. Rapamycin and COPPIX induced an increase in HO-1 mRNA after IRI; however, when the two drugs were administered together the effect was even higher (*vs IRI, Po0.05). This effect was less evident at 120 h after surgery, but still significant (**vs IRI, Po0.05). increased levels of serum creatinine in those animals (3.2770.41 and 2.9270.17 mg/dl, respectively) (Figure 6a and b).
DISCUSSION
The early function of organs harvested from deceased donors is substantially influenced by IRI, where preservation and cold ischemia time play the major roles. After transplantation, the organ is still under insult from other factors such as acute rejection and immunosuppressive drug toxicity. Moreover, minimization of immunosuppressive drugs is compromised by the risk threatened by acute rejection. 24 Rapamycin presents today as an option for those patients under risk of calcineurin inhibitor nephrotoxicity, while being able to reduce acute rejection. 25 Rapamycin has also been related to anti-tumoral and anti-viral activities. 26, 27 However, recent reports have suggested that it might prolong graft recovery after ischemic injury through its ability to inhibit protein synthesis, induce apoptosis that ultimately delay tubular regeneration. 19, 28, 29 Indeed, Fervenza et al. 14 and colleagues suggest that rapamycin might be nephrotoxic to native kidneys by analyzing a population of glomerulopathies patients. Pallet et al. 29 showed that rapamycin inhibits human epithelial cell cycles, by dramatically reducing p70S6 kinase phosphorylation and cyclin D3 expression. On the other hand, there are some data demonstrating that, in fact, rapamycin may preserve renal function in renal models of acute renal failure and have benefits in bowel ischemic injury, demonstrating the controversy about this subject that appears to be dependent on animal models. 30, 31 In clinical settings, many authors have reported that rapamycin delays early recovery of renal function posttransplantation, 15, 18, 32, 33 having a controversial impact on 1-year graft survival. Simon and colleagues analyzed 8319 patients from the United States Renal Data System and demonstrated that induction with rapamycin was independently associated, through model-adjusted logistic regression analyses, with delayed graft function. In their analyses, rapamycin use had an adjusted odds ratio of 1.42 (95% confidence interval: 1.07-1.90) of association with delayed graft function. 16 Furthermore, final organ function will largely depend on its capacity to protect itself from these aggressors via upregulation of molecules able to promote cytoprotection. Among those, HO-1 has gained a lot of attention in recent years owing to its great ability to restore organ function and tissue architecture after acute injury. Many investigators have elegantly demonstrated its role in IRI injury in organs such as the liver, kidney, and brain. 34, 35 Although the mechanism of action is still under debate, there is a consensus that heme degradation end-products are able to provide tissue protection as well. [36] [37] [38] There are little data on the HO-1 expression modulation by immunosuppressive drugs. Visner et al. 39 showed that rapamycin could actually increase HO-1 expression in an in vitro model where lung endothelial and smooth cells were cultured in the presence of platelet-derived growth factors. In addition, the enhanced HO-1 expression was specific to rapamycin, because no induction was observed in the presence of cyclosporine and responsible for rapamycin anti-proliferative capacity. 39 Besides the possibility of HO-1 expression being repressed by a GT(n) length promoter polymorphism, it has not been excluded that immunosuppression might also interfere with it. 40 We first investigated whether rapamycin could indeed aggravate an acute renal dysfunction in a mouse model of IRI, corroborating with the experimental data and with the clinical perception of an intrinsic nephrotoxicity of this drug. Then, we investigated the potential of HO-1 expression as a protective response to rapamycin acute nephrotoxicity and reasoned that HO-1 upregulation could restore renal function.
Initially, we observed animals pre-treated with rapamycin sustained a worse renal function compared to animals just subjected to IRI (Figure 1a) . At 5 days after surgery, where we do normally observe a cell regenerative response, rapamycintreated animals still had serum creatinine levels threefold higher than matched controls. When we used a more clinical relevant model, treating the animals daily with rapamycin, we observed the same pattern. Histological analyses demonstrated that ATN was significantly higher in animals exposed to an immunosuppressive drug and regeneration was inhibited at later time points (Figure 2a and b) . We could not demonstrate an acute nephrotoxicity in renal function impairment as animals just treated with the drug presented similar serum creatinine levels and we had no ATN to match the controls thereafter.
One of the most important breakthroughs in IRI pathogenesis came from pre-conditioning studies. Animals subjected to a second ischemic injury are potentially protected through upregulation of protective genes as HO-1, but also through phosphorylation of survival kinases such as the axis PI3-K-PDK-Akt-mTOR-MAPK-p70S6K in a cardiac model of IRI. [41] [42] [43] This axis is activated in response to ischemia and reperfusion, where mediated protection came about through the recruitment of downstream anti-apoptotic pathways, cell growth control, and inactivation of proapoptotic proteins such as Bad, Bax, and caspases. 41, 42 Many authors demonstrated that pharmacological activation of these kinases at the time of reperfusion, by administration of growth factors, attributes to organ protection by limiting the apoptosis. 44, 45 One downstream member of this axis is p70S6K, which phosphorylates members of the initiation complex of the protein translational machinery. This pathway is especially important in transplantation as it is inhibited by rapamycin. Indeed, Kis et al. 41 showed that rapamycin treatment inhibits the benefits of pre-conditioning in a heart model of IRI by preventing the phosphorylation of p70S6K. In clinical settings, Loverre et al. 28 demonstrated that Akt and p70S6K were highly phosphorylated within tubular and infiltrating cells in kidney graft biopsies from patients with delayed graft function. Interestingly, p70S6K phosphorylation was almost completely abolished in rapamycin-treated patients. 28 We believed that it might have also been the explanation for the renal function impairment in our study, although we have not addressed this issue specifically.
The link between these survival kinases and HO-1 has been clarified in recent years. Briefly, it seems that after injury the produced reactive oxygen species stimulate HO-1 expression via phosphatidylinositol 3 0 -kinase. Any pharmacology intervention in this cascade leads to inhibition of HO-1 expression. More recent data demonstrated that activation of Akt/PDK is also involved in the HO-1-inducible expression and that it can actually phosphorylate HO-1 at Serine 188. In this sense, we then investigated the role of HO-1 in our model. Initially, we observed that IRI induced an early and vigorous expression of HO-1, which continued to be elevated during the 5 days of observation (Figure 3 ). More interestingly, the acute toxic effect of rapamycin treatment was also accompanied by an even higher expression of HO-1. Conversely from what we saw in animals just subjected to IRI, where HO-1 expression decreases as time passed by, rapamycin-treated animals continued with higher levels of HO-1 up to 48 h after reperfusion, simultaneous to the behavior of serum creatinine, demonstrating its additional detrimental insult. In this sense, the HO-1 expression seen here could be more related to rapamycin cytotoxicity, even though we could not detect a rise in serum creatinine values in rapamycin-treated only animals. Besides that, although, mammalian target of rapamycin inhibition by rapamycin leads to inactivation of p70S6 kinase, we believed that the upstream axis is still preserved and able to upregulate HO-1 expression facing an injury. Conversely, the prior induction of HO-1 can actually protect not only the organ from IRI, but also the additional acute nephrotoxic effect of rapamycin, probably by favoring an anti-inflammatory and antiapoptotic environment (Figure 4) . Interestingly, if we delayed the administration of COPPIX, we could not see the same improvement in renal function (Figure 5a ), although this drugs could indeed increase HO-1 mRNA expression. We believe that these results demonstrate the importance of previous upregulation of HO-1 in order to have cytoprotection. The observed increment in HO-1 mRNA could be the result of the chemically induced expression summed with the stress-induced expression. Corroborating these results, the repression of HO-1 exacerbated the dysfunction superimposed by rapamycin treatment (Figure 6 ). These results are clinically relevant, as it is completely feasible to limit future graft dysfunction by modulating HO-1 expression in harvested organs during preservation time, especially those that will be randomized to use mammalian target of rapamycin inhibitors.
Rapamycin has been used in calcineurin-spared immunosuppressive situations in order to prevent the later side effects; however, cumulative evidence shows that it also has intrinsic renal toxicity. Its ability to limit tubular recovery after ischemic insults could be partially overcome by upregulation of protective genes such as HO-1.
MATERIALS AND METHODS Animals
Isogenic male C57Bl/6 mice (H2-A b ), age 5-9 weeks (25-28 g), were purchased from Animal Facilities Center from CEDEME at Universidade Federal de São Paulo. All animals were housed in individual standard cages and had free access to water and food. All procedures were previously reviewed and approved by the internal Ethical Committee of the Institution.
IRI model
Surgery was performed as previously described. 46 The mice were briefly anesthetized with ketamine-xylazine (Agribrands do Brazil, São Paulo, Brazil). A midline incision was made and both renal pedicles were cross-clamped. During the procedure, animals were kept well hydrated with saline and kept at a constant temperature (B371C) through a heating pad device. Forty-five minutes later, the microsurgical clamps were removed. The abdomen was closed in two layers and the animals were placed in single cages, warmed by indirect light until completely recovered from anesthesia. The model is associated with a mortality of 10-15% mainly in the first 48 h after reperfusion. The association of rapamycin increased the mortality to 22% in the first 48 h, although not significantly different from the control.
Study design
Animals were assigned in the following groups: group 1 (n ¼ 9), animals submitted to IRI; group 2 (n ¼ 9), animals submitted to IRI and pre-treated with rapamycin (days À1 and 0); group 3 (n ¼ 8), animals submitted to IRI and daily treated with rapamycin; group 4 (n ¼ 12), animals submitted to IRI and pre-treated with COPPIX (day À1); group 5 (n ¼ 7), animals submitted to IRI and pre-treated with COPPIX (day 0); group 6 (n ¼ 6), animals submitted to IRI and pre-treated with COPPIX (day þ 1); group 7 (n ¼ 11), animals subjected to IRI and pre-treated with rapamycin (days À1 and 0) and COPPIX (day À1); group 8 (n ¼ 11), animals subjected to IRI and pre-treated with rapamycin (days À1 and 0) and COPPIX (day 0); group 9 (n ¼ 11), animals subjected to IRI and pre-treated with rapamycin (days À1 and 0) and COPPIX (day þ 1); group 10 (n ¼ 11), animals subjected to IRI and pre-treated with SnPPIX; and group 11 (n ¼ 7), animals pre-treated with rapamycin (days À1 and 0) and SnPPIX. Animals were killed at days 1, 2, and 5 after reperfusion, except in groups 4 and 7, where the animals were killed 24 and 120 h after surgery, and in groups 5, 6, 8, 9, 10, and 11, where the animals were killed 24 h after surgery. Additionally, animals were subjected to the surgical procedure without renal vessels occlusion (sham), pre-treated or not with all drugs, in combination or not (n ¼ 5).
Drugs
Rapamycin was given in a dose of 3 mg/kg, 19 per gavage, 1 day before and at the day of IR (days À1 and 0), or daily until the animal was killed. The drug (1 mg/ml) was dissolved in a solution of 0.9% NaCl and ethanol (30:55:15) . COPPIX and SnPPIX were given intraperitoneally at 5 mg/kg and 30 mm/kg, 1 day before the surgery.
Renal function outcome
Blood was collected for serum creatinine measurements and kidneys were harvested for histological and mRNA analyses at the end points. Serum creatinine was measured in duplicate by the Jaffé modified method (Roche, Mannheim, Germany). The extension of tubular necrosis (ATN) morphology and patterns of regeneration in the outer medulla was examined by blinded morphometric assessment using a computer-assisted image system with an Olympus BX40F-3 microscope (Olympus Optical Company, Tokyo, Japan) and the software program KS300 program (Zeiss, Göttingen, Germany). The results were expressed as a ratio of the injured area related to total area (14 58 467 mm 2 ). Twenty-five random fields were counted at an original magnification Â 835, almost covering all outer medulla, corresponding to an area of 3.64 61 675 mm 2 , for each animal, per lamina. For morphometric analyses, ATN and regeneration were analyzed at 24 and 120 h after reperfusion. Tubular necrosis pattern included: loss of cytoplasmatic and nuclear membranes integrity, loss of brush border, vacuolization of tubular epithelial cells, and presence of intratubular debris. Tubular regeneration or repair was characterized by attenuated epithelium enclosing dilated lumens filled with proteinaceous fluid or granular material. Mitotic figures may be present or tubules were lined by basophilic epithelium, with basophilic cytoplasm and hyperchromatic nuclei or vesicular nuclei with prominent nucleoli.
Gene profiles
Kidney samples were quickly frozen in liquid nitrogen. Total RNA was isolated from kidney tissue using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) methodology and RNA concentration was determined by spectrophotometer readings at absorbance 260 nm. First-strand cDNAs were synthesized using the MML-V reverse transcriptase (Promega, Madison, WI, USA). Reverse transcriptionpolymerase chain reaction was performed using the SYBR Green real-time polymerase chain reaction assay (Applied Biosystem, Foster City, CA, USA). Sequences of primers used were: HO-1 (sense) 5 0 -TCA GTC CCA AAC GTC GCG GT-3 0 and (anti-sense) 5 0 -GCT GTG CAG GTG TTG AGC C-3 0 and hypoxanthine guanine phosphoribosyltransferase (sense) 5 0 -CTC ATG GAC TGA TTA TGG ACA GGA C-3 0 and (anti-sense) 5 0 -GCA GGT CAG CAA AGA ACT TAT AGC C-3 0 . Cycling conditions were as follows: 10 min at 951C followed by 45 cycles of 20 s at 951C, 20 s at 53.51C, and 20 s at 721C. Analysis used Sequence Detection Software 1.9 (SDS). The mRNA expression was normalized to hypoxanthine guanine phosphoribosyltransferase abundance. Subsequently, all data were expressed relative to the expression of the matched controls (sham).
Statistics
All data were described as mean7s.d. Parametric and nonparametric tests were performed when the sample distribution were considered normal or not. Different evolutions among the groups were compared using analysis of variance followed by Tukey's or Dunn's test for individual comparisons among groups. The null hypothesis was rejected when Po0.05. All statistical analyses were performed with aid of Stata Statistical Software 5.0 (Stata Corporation, College Station, TX, USA).
